ONCY News and Press, Oncolytics Biotech Inc. From 05/26/23

2023-05-26 14:01:57 ET Oncolytics Biotech ( NASDAQ: ONCY ) shed ~16% on Friday after announcing results from its Phase 2 trial for experimental therapy pelareorep as a combination regimen in patients with a certain type of breast cancer. Results shared ahead of a presentatio...

2023-05-26 13:21:20 ET Gainers: Elevation Oncology ( ELEV ) +70% . Alarum Technologies ( ALAR ) +61% . Bright Health Group ( BHG ) +56% . Onfolio Holdings ( ONFO ) +35% . D-Wave Quantum ( QBTS ) +31% . Marvell Technology ( ...

Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting Canada NewsWire Key opinion leader webinar to take place on June 5, 2023 at ...

2023-05-26 10:45:42 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – May 26, 2023 – USA News Group –  The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 20...

2023-05-26 08:30:43 ET Palm Beach, FL – May 26, 2023 – FinancialNewsMedia.com News Commentary – Metastatic breast cancer is the advanced stage of breast cancer, including cases wherein cancer has spread to the other parts of the body from the breast. It is a...

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract Canada NewsWire 31% week-16 overall response r...

2023-05-05 12:57:59 ET Oncolytics Biotech press release ( NASDAQ: ONCY ): Q1 GAAP EPS of -$0.10 in-line. $29.7 million in cash, cash equivalents, and marketable securities as of March 31, 2023 provides projected cash runway for at least 12 months. Shares +11% . ...

2023-05-05 12:37:08 ET Oncolytics Biotech Inc. (ONCY) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Jon Patton – Director-Investor Relations and Communications Matt Coffey – Chief Executive Officer Thomas Heineman ...

2023-05-04 12:44:59 ET Oncolytics Biotech ( NASDAQ: ONCY ) is scheduled to announce Q1 earnings results on Thursday, May 4th, after market close. The consensus EPS Estimate is -$0.10 (+16.7% Y/Y) and the consensus Revenue Estimate is $0M. Over the last 3 months, EPS es...

Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting Canada NewsWire Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO and CALGARY, ...